Want to see SE:SCIB full AI Analyst Report?
SciBase Holding AB (SCIB) Stock Price & Analysis
SCIB Stock Chart & Stats
- Day’s Range
- SEK 12.20 - SEK 12.55
- 52-Week Range
- SEK 12.20 - SEK 51.34
- Previous Close
- SEK 12.65
- Volume
- N/A
- Average Volume (3M)
- 9,631
- Market Cap
- SEK 174.38M
- Enterprise Value
- SEK 318.37M
- Total Cash (Recent Filing)
- SEK 37.15M
- Total Debt (Recent Filing)
- SEK 23.21M
- Price to Earnings (P/E)
- ―
- Beta
- -0.13
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
TTM revenue growth of about 14.2%, following steady expansion since 2021, indicates improving commercial traction for Nevisense. If maintained, this broader revenue base can help spread fixed costs and provide a foundation for eventual operating leverage over the next several quarters.
Gross Margin
A TTM gross margin near 59% indicates that the company retains meaningful value after direct costs on its medical-device sales. This provides a potentially supportive base for reinvestment and future profitability if revenue scale increases faster than operating expenses.
Moderate Current Leverage
Current leverage is moderate, with debt-to-equity around 0.41 and total debt relatively contained against assets. This gives SciBase a more manageable financial structure than its prior peak and preserves some flexibility while the business works toward improved earnings.
Bears Say
Persistent Losses
The company remains deeply unprofitable, with a TTM net margin near -208% and a cost base still far ahead of scale. Persistent losses can absorb capital, delay self-funded growth, and make the durability of the business model dependent on a substantial improvement in operating efficiency.
Cash Burn
Materially negative operating and free cash flow show that SciBase is not yet funding operations internally. Continued cash burn can constrain investment choices and increase reliance on external funding until revenue growth and cost control improve enough to support sustainable cash generation.
Balance-Sheet Volatility
The sharp increase in debt-to-equity to about 3.46 during 2025 demonstrates that SciBase's financial position can deteriorate quickly when losses pressure equity. Although leverage later improved, renewed losses could again raise funding needs and financing or dilution risk.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
What is SciBase Holding AB’s market cap?
When is SciBase Holding AB’s upcoming earnings report date?
How were SciBase Holding AB’s earnings last quarter?
Is SciBase Holding AB overvalued?
Does SciBase Holding AB pay dividends?
What is SciBase Holding AB’s EPS estimate?
How many shares outstanding does SciBase Holding AB have?
What happened to SciBase Holding AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SciBase Holding AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Pia Renaudin
- Employees
- 50
- Website
- www.scibase.com
- Address
- Landsvägen 39, Sundbyberg, AB, 172 63, SE
SciBase Holding AB (SCIB) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |
